{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:32:44Z","timestamp":1793219564538,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.therap.2026.02.003","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T17:05:29Z","timestamp":1772125529000},"page":"427-429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hyperprolactinemia following a single dose of risperidone: A case report"],"prefix":"10.1016","volume":"81","author":[{"given":"Aur\u00e9lie","family":"Bobet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gael","family":"Galliot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Bougon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Rouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Barus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0173-6437","authenticated-orcid":false,"given":"Tanguy","family":"Taillefer de Laportaliere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2026.02.003_bib0080","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.3390\/jcm8122203","article-title":"Hyperprolactinaemia","volume":"8","author":"Samperi","year":"2019","journal-title":"JCM"},{"key":"10.1016\/j.therap.2026.02.003_bib0085","doi-asserted-by":"crossref","first-page":"1337274","DOI":"10.3389\/fpsyt.2024.1337274","article-title":"Treatment of antipsychotic-induced hyperprolactinemia: an umbrella review of systematic reviews and meta-analyses","volume":"15","author":"Jiang","year":"2024","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.therap.2026.02.003_bib0090","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2026.02.003_bib0095","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.therap.2022.03.001","article-title":"Pharmacovigilance and drug safety: fair prescribing and clinical research","volume":"77","author":"Montastruc","year":"2022","journal-title":"Therapies"},{"key":"10.1016\/j.therap.2026.02.003_bib0100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2515\/therapie\/2013016","article-title":"Updating the French method for the causality assessment of adverse drug reactions","volume":"68","author":"Arimone","year":"2013","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2026.02.003_bib0105","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.therap.2026.02.003_bib0110","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/sj.npp.1300412","article-title":"From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions","volume":"29","author":"Emiliano","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.therap.2026.02.003_bib0115","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1192\/apt.bp.115.014928","article-title":"Management of antipsychotic-induced hyperprolactinaemia","volume":"23","author":"Gupta","year":"2017","journal-title":"BJPsych Advances"},{"key":"10.1016\/j.therap.2026.02.003_bib0120","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/archpsyc.1976.01770030003001","article-title":"The effect of neuroleptics on serum prolactin in schizophrenic patients","volume":"33","author":"Meltzer","year":"1976","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.therap.2026.02.003_bib0125","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1124\/jpet.102.035303","article-title":"The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats","volume":"302","author":"Kapur","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.therap.2026.02.003_bib0130","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00213-005-0230-1","article-title":"Effects of the atypical antipsychotics olanzapine and risperidone on plasma prolactin levels in male rats: a comparison with clinical data","volume":"184","author":"Rourke","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.therap.2026.02.003_bib0135","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4088\/JCP.08m04307yel","article-title":"Positron emission tomography measurement of dopamine D2 receptor occupancy in the pituitary and cerebral cortex: Relation to antipsychotic-induced hyperprolactinemia","volume":"71","author":"Arakawa","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.therap.2026.02.003_bib0140","doi-asserted-by":"crossref","first-page":"874705","DOI":"10.3389\/fpsyt.2022.874705","article-title":"Risperidone induced hyperprolactinemia: from basic to clinical studies","volume":"13","author":"Stojkovic","year":"2022","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.therap.2026.02.003_bib0145","article-title":"Prolactin elevations and permeability glycoprotein","volume":"21","author":"El-Mallakh","year":"2019","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.therap.2026.02.003_bib0150","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1055\/s-2002-25026","article-title":"The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients","volume":"35","author":"Bondolfi","year":"2002","journal-title":"Pharmacopsychiatry"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595726000466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595726000466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:50:29Z","timestamp":1793217029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595726000466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0040595726000466"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2026.02.003","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperprolactinemia following a single dose of risperidone: A case report","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2026.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}